Yahoo Finance

Roth MKM last night initiated coverage of Longeveron (LGVN) with a Buy rating and $10 price target The firm says its investment thesis is driven by the 100% transplant-free survival benefits at the end of five years delivered by Lomecel-B in hypoplastic left heart syndrome. HLHS presents a grave danger to infant survival despite three-stage palliative surgeries, As previously reported,

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on LGVN:

• Longeveron initiated with a Buy at Roth MKM

• Longeveron reports Q3 EPS (34c), consensus (44c)

• Longeveron appoints Blass as Chief Technology Officer

• Longeveron Inc. (LGVN) Q3 Earnings Cheat Sheet

• Longeveron presents Lomecel-B long-term transplant-free survival data in HLHS